Growth Metrics

Madrigal Pharmaceuticals (MDGL) Amortization of Deferred Charges (2022 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Amortization of Deferred Charges for 4 consecutive years, with $468000.0 as the latest value for Q4 2025.

  • Quarterly Amortization of Deferred Charges fell 2.9% to $468000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, down 23.22% year-over-year, with the annual reading at $1.6 million for FY2025, 23.22% down from the prior year.
  • Amortization of Deferred Charges for Q4 2025 was $468000.0 at Madrigal Pharmaceuticals, up from $329000.0 in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $753000.0 in Q4 2023, with the low at $178000.0 in Q2 2022.
  • Average Amortization of Deferred Charges over 4 years is $460266.7, with a median of $468000.0 recorded in 2025.
  • The sharpest move saw Amortization of Deferred Charges skyrocketed 211.24% in 2023, then plummeted 35.99% in 2024.
  • Over 4 years, Amortization of Deferred Charges stood at $306000.0 in 2022, then soared by 146.08% to $753000.0 in 2023, then tumbled by 35.99% to $482000.0 in 2024, then decreased by 2.9% to $468000.0 in 2025.
  • According to Business Quant data, Amortization of Deferred Charges over the past three periods came in at $468000.0, $329000.0, and $371000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.